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Summary
Diagnosis and treatment of breast cancer has progressed rapidly in recent 20 years. The diagnosis was fi rst based on 
clinical appearance that changes after the introduction of mammography in the diagnosis. Development of radiological 
techniques has led to the detection of a small and non-palpable lesions, and surgeons are increasingly applied conserving 
procedures for breast cancer. Therefore, today is a very important multidisciplinary team in the treatmentof patients with 
breast cancer. A pathologist is a key member of the multidisciplinary team who determines the prognostic and predictive 
factors for patients with breast cancer which require some standardized protocols and processing of tissue samples.
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PATOHISTOLOŠKI STANDARDI ZA KARCINOM DOJKE
Sažetak
Dijagnostika i liječenje karcinoma dojke je posljednjih 20 godina vrlo brzo napredovalo. U prvo vrijeme dijagnoza se 
postavljala na temelju kliničkih nalaza što se promijenilo uvođenjem mamografi je. Razvoj radioloških metoda doveo je do 
otkrivanja malih i nepalpabilnih lezija te su kirurzi počeli primjenjivati poštedne kirurške zahvate nakon kojih slijedi adju-
vantno liječenje. Zbog toga je danas vrlo važan multidisciplinarni tim u liječenju bolesnica s karcinomom dojke. Patolog je 
ključni član multidisciplinarnog tima jer mora odrediti brojne prognostičke i prediktivne čimbenike za bolesnice s karcino-
mom dojke štosve zahtjeva odgovarajuće standardizirane protokole i postupke za uzorke tkiva.
KLJUČNE RIJEČI: karcinom dojke, patologija, prognostički i prediktivni čimbenici
INTRODUCTION
The diagnosis and treatment of breast cancer 
has rapidly evolved over the past 20 years. In the 
fi rst part of the 20th century, treatment of breast 
cancer consisted of radical mastectomy, but adju-
vant systemic treatment and adjuvant radiothera-
py did not play a major role. Diagnosis of breast 
cancer was mostly made based on clinical presen-
tation, later aided by mammography and often 
combined with frozen section pathology confi r-
mation. Starting in the 1980s, there have been im-
portant alterations in the diagnosis and treatment 
of breast cancer, having an important impact on 
the diagnostic procedure employed by patholo-
gists.
Radiological techniques have greatly impro-
ved, and in addition, population-based mammog-
raphy screening is increasingly off ered, especially 
to women over 50 years of age. These develop-
ments have led to the detection of many small 
non-palpable lesions, including ductal carcinoma 
in situ.
Histopathological features play an important 
role in guiding the treatment decisions. In addi-
tion, genetic research is starting to have an in-
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creasing impact on therapy by providing prog-
nostic and predictive factors (1).
PRE-TREATMENT DIAGNOSIS
A palpable mass is the most common clinical 
sign of invasive breast carcinoma, although skin 
retraction, nipple inversion, nipple discharge and 
less commonly, a change in the size or shape of the 
breast may still be found. Rarely, we can see a 
change in the colour or texture of the skin. All the 
symptoms of breast cancer may also be caused by 
benign breast disease. Therefore, diagnosis of 
breast lesions is based on clinical examination, ra-
diology and pathology. When abnormalities are 
found, the diagnostic fi ndings should be discussed 
among specialists from three disciplines involved 
in the diagnostic work-up:the surgeon, the radi-
ologist and the pathologist. The evaluation with 
imaging and histological sampling with core bi-
opsy (CB) or fi ne-needle aspiration cytology 
(FNAC) are indicated to establish a defi nitive di-
agnosis.
FNAC and CB have been extensively used 
for years in the diagnosis of breast lesions and 
have good sensitivity for the diagnosis of malig-
nancy in palpable lesions (2). There is evidence 
that CB is more sensitive for the detection of im-
palpable lesions and is recommended for the eval-
uation of microcalcifi cations and FNAC fi ndings 
that are suspicious (3). Experience to date has in-
dicated that there is excellent correlation between 
the fi ndings of CB with those of open biopsy. The 
use of strict diagnostic criteria, coupled with im-
munohistochemistry, is useful to avoid a misdiag-
nosis. However, a defi nitive diagnosis is not al-
ways possible and a classifi cation that includes 
borderline categories such as ‘suspicious’, ‘equiv-
ocal’ or ‘uncertain malignant potential’ is useful in 
patient management (4). When a clearly dis-
tiguishable mass is present, two or three biopsies 
are usually suffi  cient to obtain a defi nite diagno-
sis. When the radiological/clinical fi nding is an ar-
chitectural distortion or microcalcifi cations, more 
biopsies are usually required to obtain a certain 
diagnosis. Histological grade can be assessed on 
CB with about 70% of agreement with the grade 
determined in the surgical specimen (5). Both 
FNAC and CB can give an indication of histologi-
cal type, but neither is defi nitive because of the 
existence of tumours with mixed types and het-
erogeneity of tumour. Estrogen receptor status 
and HER-2 status can be reliably assessed on CB, 
with agreements of about 98-99%. The analysis of 
prognostic and predictive factors using FNAC 
should be limited to cases of distant metastasis 
and cases with no available tissue material. Ultra-
sound-guided CB or FNAC of axillary lymph 
nodes can be helpful in the management of inva-
sive carcinoma, for the preoperative diagnosis of 
metastases (6). The B ( B1-B5) category system is 
applied to tissue samples of the primary breast 
cancer obtained by CB. Pathologists need to be 
highly qualifi ed and experienced in breast diseas-
es as they are key players in interdisciplinary com-
munication and decision-making (7).
EXAMINATION OF SURGICAL 
SPECIMEN CONTAINING NONINVASIVE 
BREAST CANCER
Knowledge of the lobular arcitecture of the 
mammary gland is a prerequisite for understand-
ing noninvasive ductal cancer (DCIS). DCIS takes 
its origin from the terminal duct lobular unit 
(TDLU), starting with distension of the ductular 
structure and unfolding of lobules by the prolifer-
ating tumor cells. Further expansion then leads to 
the involvement of the extralobular ductal system. 
The ductal-lobular system forms segments from 
the nipple to the periphery, which appear to be 
pyramid-shaped with peak pointing towards the 
nipple (8). Therefore, these segments do not follow 
the geometry of the artefi cial system of qudrants. 
DCIS most frequntly occurs within one segment, 
very rarely foci are found in clearly diff erent seg-
ments. Radiological microcalcifi cations are the 
only clue for detection of DCIS, but can alsobe de-
tected as incidental fi nding showing no microcal-
cifi cations (8). The pathologist must rely on radio-
logically detected microcalcifi cations to identify 
areas suspicious for DCIS. The pathologist must: 
fi nd a lesion, to determine the size of the lesion 
and the most important condition of the resection 
margins. Therefore, immediately after removing 
the surgical specimen the surgeon should mark 
the margins( lateral – long stitch, medial- medium 
stitch, superior- 2 short stitches)and then places 
the excision specimen on a foil with schematic 
drawing of breast outlines fi xed the specimen 
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with cannulas. The radiologist then performs 
specimen radiography and marks the margins of 
the microcalcifi cation area with several pins. This 
marking for the pathologist is done independent-
ly of the preoperative marking for surgeon. Mark-
ing the surface of excision tissue is essential for 
microscopic identifi cation of the original resection 
margins. Therefore, pathologist should paint the 
specimen surface with marker that adhere to the 
tissue during fi xation, dehydration, embedding, 
cutt ing and staining and must be visible at micros-
copy. The specimen should be serially sectioned 
from mamillary pole to the periphery of the seg-
ment (9). Standardized sampling enables the pa-
thologist to identify all lesions and determine their 
size. Size of breast carcinoma is the most impor-
tant factor for management of patients eligible for 
breast-conserving therapy. Data on the margins 
give highly reliable information about residual tu-
mors in the event of re-excisions. Immunohisto-
chemically, the pathologist must determine the 
status of estrogen and progesterone receptors.
Intraoperative frozen section examinations 
can only be justifi ed in two situations. Firstly, in 
the case when an invasive tumor was detected nei-
ther by mammography nor by ultrasound. Sec-
ondly, when DCIS is centrally located and when is 
operation with preservation of the nipple.
The pathologist responsibilities include as-
sessment of suspicious fi ndings, participation in 
preoperative therapy planning for carcinomas, in-
tra and postoperative diagnostics as well as qual-
ity assurance.
EXAMINATION OF SURGICAL SPECIMEN 
CONTAINING INVASIVE BREAST CANCER
Nowadays, 60-70% of patients undergo 
breast-conserving therapy. Standardized work up 
of surgical specimens, obtained as part of breast-
conserving therapy, is extremely important. The 
surgeon should markthe excision specimen so 
that the pathologist can reconstruct the orienta-
tion of the resection margins ( lateral – long stitch, 
medial - medium stitch, superior- 2 short stitches). 
The resection margins should be marked with ink 
by a pathologist.After this procedure, the patholo-
gist must measure the size of the tissue sample in 
three dimension, determine the dimensions of the 
skin if it is present, to determine the size of the 
tumor in three dimensions and must record the 
localization wire if present in cases of small tu-
mours (10).
To obtain optimal morphology inthe histolo-
gy sections, and to obtain optimal immunohisto-
chemical staining results, the resection specimen 
should be cut into thin slices immediately after 
surgery. For microscopic examination the pathol-
ogist should be obtainedand processed for paraf-
fi n sections full diameter of the tumour and its 
surroundings, small part of the tumour to perform 
immunohistochemistry, if there are macroscopical 
or radiological abnormalities in the tissue sur-
rounding the invasive tumour, these areas should 
be sampled. If the surrounding tissue is without 
abnormalities, it is necessary to take at least two 
sections from macroscopically normal breast tis-
sue.
On slides stained with hematoxylin eosin 
(HE), pathologist must determine the prognostic 
and predictive factors for breast cancer. This in-
cludes the histological type of cancer (11), the de-
gree of tumour diff erentiation (12), mitotic counts, 
lymphovascular invasion, estrogen and progester-
one receptors (13), protein HER-2 (14) and prolif-
erative index Ki-67 (15).
Receptors are determined by immunohisto-
chemistry and the results are expressed as the per-
centage of positive cells and intensity of staining. 
Staining for estrogen and progesterone receptor is 
always nuclear in localization and in most insti-
tutes all patients with a tumour in which more 
than 10% or more 1% of the tumour cells show 
positive staining regardless of the intensity of 
staining are candidates for adjuvant hormonal 
therapy. According to the consensus of the St Gal-
len 2014. cut-off  of the progesterone receptors is 
20%. This value best separating luminal type A 
from luminal type B breast cancer. Values below 
20% indicate that the progesterone receptors are 
negative or low16. When negative staining for es-
trogen and/or progestrone receptor is seen, it is 
important to confi rm that staining of the hormone 
receptor-negative case has been successful. This 
can usually be tested, since the majority of normal 
breast tissues contain some nuclei ducts and lob-
ules that are positive for estrogen and progester-
one receptor. If no normal breast epithelial cells 
are found to show positive staining, the hormone 
receptor assays should be repeated on another tu-
mour block.
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HER-2 gene amplifi cation is observed in 15-
30% of invasive breast cancers and leads to HER-2 
receptor overexpression. HER-2 positive invasive 
breast cancers respond favourable to therapies 
that specifi cally target the HER-2 protein, there-
fore it is very important today to identify candi-
dates for this type of targeted therapy. Several 
technologies are available for determining HER-2 
status, but the two most commonly used are 
 immunohistochemistry (IHC), which measures 
HER-2 protein expression, and CISH (chromogen 
in situ hybridisation) which detects HER-2 gene 
amplifi cation a method that is often used today in 
the pathology than FISH (fl uorescence in situ hy-
bridisation). The interpretation of the results is 
based on the intensity and percentage of stained 
cells. The most commonly used score system is 0, 
1+ (negative results) , 2+ and 3+ (positive results). 
A 2+ is considered equivocal and should be fol-
lowed by retesting by CISH. Women with IHC 3+ 
tumours are candidates for therapy with trastu-
zumab, but women with 2+ tumour should be re-
tested and if the results show amplifi cation of 
gene of those are candidates for trastuzumab. To 
ensure the highest possible accuracy, pathology 
centers must standardise methodologies and test-
ing procedures.
Proliferative index is also very important and 
is determined by immunohistochemistry by mo-
noclonal antibody Ki-67. Positive reaction is nu-
clear reaction and are counted positive nuclei in 
1000 tumour cells on the high magnifi cation and 
the results obtained is expressed as a percentage 
of positive nuclei. According to St Gallen consen-
sus cut of value is 20% of positive cells, which 
means that below this value is low and value 
above 20% is high proliferative index (16).
Based on the receptors, HER-2 status and 
proliferative index breast cancers are classifi ed 
immunophenotypically into fi ve subgroups: lumi-
nal type A, luminal type B HER-2 negative, lumi-
nal type B Her-2 positive, HER-2 positive ( non-
luminal type) and triple negative tumours. Based 
on the immunophenotype of the cancer patients 
receive appropriate therapy. The multi-gene test-
ing remains inaccesible for the majority of women 
with early breast cancer, therefore is adopted clin-
ico-pathological testing, now expressed in surro-
gate IHC-based classifi cation.
In the widest sense, post-therapy eff ects in-
clude morphololgical and biological alterations in 
cancer and normal tissue after any treatment. The 
patients have no or litt le response, and the major-
ity has a partial response to therapy. The extent of 
this response is associated with outcome. Identify-
ing stage after treatment is important and pro-
vides additional prognostic information. Histo-
pathologically, then staging a label y. The response 
in lymph nodes has more prognostic importance 
than does response in the breast. Small metastases 
after treatment, including isolated tumour cells, 
are representative of an incomplete pathological 
response (17).
EXAMINATION OF AXILLARY 
LYMPH NODES
Sentinel node biopsy
One to three sentinel node biopsies are ob-
tained from axilla. In some institutes, frozen sec-
tion evaluation of the sentinel node biopsy is per-
formed, but many institutes prefer evaluation on 
paraffi  n section. There is agreement that one he-
matoxylin and eosin (HE) stained section of the 
sentinel node should always be evaluated. At vari-
ous levels of the sentinel node is recommended to 
do immunohistochemistry with antibodies direct-
ed against keratin (pancytokeratin, cytokeratins of 
low molecular weight and cytokeratins of high 
molecular weight). The size of lymph node metas-
tasis should be categorized as follows:
>2 mm  = a macrometastasis
0.2-2 mm  = a micrometastasis
< 0.2 mm  =  isolated tumour cells (the tumour cells 
can often only be detected by immu-
nohistochemistry)
Axillary dissection
When an axillary dissection is performed, 
fatt y tissue is removed which contains the lymph 
nodes. The pathologist should carefully identify 
all the lymph node that are present in the resec-
tion specimen, and each of these lymph nodes 
should be embedded for histological examination. 
Lymph nodes up to 1cm can be totally embedded, 
larger lymph nodes should be bisected or lamel-
lated and fully embedded. The number of lymph 
nodes containing metastases should be recorded. 
In addition, the diameter of the largest lymph 
node metastasis should be recorded and the inva-
sion of the capsule.
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CONCLUSION
Numerous studies in recent years have iden-
tifi ed many prognostic and predictive factors for 
breast cancer. Most of them determined pathohis-
tologically, which resulted in a large responsibili-
ty for pathologists. In addition, the pathologist 
has become a key person in a multidisciplinaty 
team of breast cancer and the key personin imple-
mentation of specifi c individual therapy.
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